Friday,  December 21, 2012 • Vol. 13--No. 156 • 26 of 31 •  Other Editions

(Continued from page 25)

rates on million-dollar earners was abruptly scrapped Thursday evening.
• The measure "did not have sufficient support from our members to pass," House Speaker John Boehner, R-Ohio, conceded in a brief statement.
• At the White House, Press Secretary Jay Carney said that Obama's "main priority is to ensure that taxes don't go up on 98 percent of Americans and 97 percent of small businesses," citing statistics associated with Obama's campaign promise to increase top tax rates on household earning more than $250,000 a year.
• "The President will work with Congress to get this done and we are hopeful that we will be able to find a bipartisan solution quickly that protects the middle class and our economy," Carney said. Pointedly, the statement didn't say whether Obama would work with Boehner to revive stalled talks with Boehner or turn to the Democratic-controlled Senate to try to salvage the situation.
• Boehner's attempt to tactically retreat from a longstanding promise to maintain Bush-era tax rates for all was designed to gain at least some leverage against Obama and Senate Democrats in the fiscal cliff endgame. Thursday's drama was a major personal defeat for the Speaker, who retains the respect and affection of his tea party-infused conference, but sometimes has great difficulty in getting them to follow his leadership.
• ___

AP IMPACT: Federal crackdown on foreign HGH has led to record sales of the drug by Big Pharma

• A federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's biggest pharmaceutical companies, an Associated Press investigation shows.
• The crackdown, which began in 2006, reduced the illegal flow of unregulated supplies from China, India and Mexico.
• But since then, Big Pharma has been satisfying the steady desires of U.S. users and abusers, including many who take the drug in the false hope of delaying the effects of aging.
• From 2005 to 2011, inflation-adjusted sales of HGH were up 69 percent, according to an AP analysis of pharmaceutical company data collected by the research firm IMS Health. Sales of the average prescription drug rose just 12 percent in that same period.
• ___

(Continued on page 27)

© 2012 Groton Daily Independent • To send correspondence, click here.